Press releases
These press releases are intended for journalists and analysts/investors.
-
GSK establishes Immunology Network to collaborate with academic research scientists
Global pharmaceutical company, GSK has launched a new immunology research collaboration model
-
Boostrix availability
GSK prioritises whooping cough vaccine availability for those most at risk of the disease and confirms uninterrupted supply of Boostrix®
-
GSK first in Australia with new business model for the pharmaceutical industry
The changes represent a fundamental shift in the GSK business model and will come into effect in Australia for 2016
-
Australian manufacturing innovation starts pilot with the hope it could reduce cost of vaccination in developing world
GSK Australia today opened a new pilot vaccine facility at its Boronia site to manufacture a vaccine testing a new production method
-
Amgen reacquires all rights to Prolia® (denosumab) in Australia
Amgen and GSK to Work Together to Ensure a Smooth Transition for Prolia® Patients and Their Physicians
-
Winning research team unlocks immune system secret - specialised T cells attack microbes as they make their vitamins
A research partnership between The University of Melbourne and Monash University has won $80,000 to help continue groundbreaking work
-
GSK supports National Immunisation Program with four strain flu vaccine for 2016
GSK Australia is proud to be partnering with the Australian Government to provide a quadrivalent (four-strain) influenza vaccine
-
Research shows 53 per cent of Australians never consult a GP for hay fever advice
New consumer research[1] shows one in two (53%) Australians with hay fever have never sought advice from their GP to manage their symptoms
-
GSK's parting gifts to local community
GSK is making generous donations to local educational facilities in recognition of the community in which it has played a key role
-
GSK and Sun Pharma complete Opiates transaction
GlaxoSmithKline (GSK) and Sun Pharma have successfully completed the transfer of GSK’s Australian Opiates business that was acquired
-
Pharmacy Level Recall - Bactroban® Cream (mupirocin calcium 2%) and Bactroban® Nasal Ointment (mupirocin calcium 2%)
GSK Australia, in consultation with the Therapeutic Goods Administration (TGA), is initiating a pharmacy level recall of five batches
-
Update on supply of Zovirax Ophthalmic Ointment (aciclovir 3%)
Zovirax Ophthalmic Ointment (aciclovir 3%) is impacted by an ongoing global supply constraint with no confirmed resupply date in Australia
-
GSK Australia releases 2014 Responsible Business Report
GSK Australia and New Zealand have published the third annual responsible business report, outlining key achievements in health, community
-
INTERNATIONAL MEN’S HEALTH WEEK 2015: Sam Newman exposes neglected men’s health issue
Australian campaign focuses on enlarged prostates
-
GSK Australia launches new vaccination picture book for Aboriginal and Torres Strait Islanders
GSK Australia has a new immunisation resource for Aboriginal and Torres Strait Islanders this month to encourage families to be proactive
-
GSK granted $1 million by Federal Government for advanced manufacturing project in Boronia
GSK Australia is a recipient of a grant through of the Federal Government’s Manufacturing Transition Programme worth AUD$1 million
-
GSK Australia Reports 2014 results to ASIC
GlaxoSmithKline (GSK) Australia reported to the Australian Securities and Investment Commission (ASIC) sales revenue of $906m in 2014
-
GSK Award for Research Excellence opens
Nominations for GSK’s Award for Research Excellence (ARE) open today for the 35th year running
-
Supply update: Fluarix Tetra and Fluarix
GSK advises supply of new quadrivalent (four-strain) influenza vaccine, Fluarix® Tetra, recently launched in Australia
-
GSK discloses payments to Australian healthcare professionals in 2014
In 2014, GSK Australia made payments totalling $3,466,951 to healthcare professionals (HCPs) and health-related organisations
